Intraocular Lymphoma Treatment Market Size to Surpass US$ 1.81 Billion by 2031 – Growth Plus Reports

Advertisement

Newark, New Castle, USA, June 15, 2023 (GLOBE NEWSWIRE) — The market analysis of the global intraocular lymphoma treatment market was conducted by Growth Plus Reports in 2022 and valued at US$ 1.02 billion. The market is expected to hit a revenue CAGR of 6.60% to reach US$ 1.81 billion by 2031.

Analysis of the global market for intraocular lymphoma treatment indicates that during the forecast period, revenue share is likely to increase significantly. The intraocular lymphoma treatment market refers to the pharmaceutical sector that focuses on developing and providing therapeutic interventions for intraocular lymphoma (IOL), a rare form of non-Hodgkin’s lymphoma that primarily affects the eyes. Intraocular lymphoma is characterized by the presence of malignant lymphocytes within the eye, either in the vitreous humor (the gel-like substance in the center of the eye) or in the retina.

Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/intraocular-lymphoma-treatment-market/8936

Advertisement

                           Intraocular Lymphoma Treatment Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 1.02 billion
Revenue Forecast in 2031 US$ 1.81 billion
CAGR 6.60%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Type, Drug Class, End User, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The market for intraocular lymphoma treatment is relatively small due to the rarity of the disease. However, advancements in diagnostic techniques and increased awareness among healthcare professionals have led to earlier detection and improved treatment outcomes. Additionally, ongoing research and clinical trials focused on developing novel therapies and targeted treatments for intraocular lymphoma are expanding the treatment options available to patients.

Recent Development in the Intraocular Lymphoma Treatment Market: 

  • In December 2022, US FDA received the new medication application for ADX-2191, which was submitted for the purpose of treating primary vitreoretinal lymphoma. The NDA for ADX-2191, a methotrexate injection, is based on the phase 3 GUARD study, which examined the drug’s safety and effectiveness in treating primary vitreoretinal lymphoma as well as in preventing proliferative vitreoretinal disease. The US FDA gave ADX-2191 the classification of Orphan Drug.

Competitive Landscape:

A list of the prominent players operating in the global market for intraocular lymphoma treatment includes: 

  • Pfizer Inc.   
  • Astex Pharmaceuticals                                                          
  • Celgene Corporation                                                             
  • F. Hoffmann-La Roche Ltd.                                                   
  • Genentech Inc.     

Request for Customization – https://www.growthplusreports.com/inquiry/customization/intraocular-lymphoma-treatment-market/8936

 Market Segmentation: 

Based on type, the global intraocular lymphoma treatment market is segmented into vitreoretinal and uveal.    

Based on drug class, the global intraocular lymphoma treatment market is segmented into methotrexate, cisplatin, and rituximab.

The rituximab segment accounted for the majority of revenue share in the global intraocular lymphoma treatment market.

Based on end user, the global intraocular lymphoma treatment market is segmented into hospitals and specialty clinics.

Concusion:

Global market research on the intraocular lymphoma treatment market was done in-depth by Growth Plus Reports. We looked at the core market traits, noteworthy investment prospects, regional growth trends, ten-year revenue projections, rival market participants, and mergers and acquisitions. The intraocular lymphoma treatment market is a specialized segment within the broader field of oncology. Although the disease is rare, advancements in diagnostic techniques and treatment approaches, including chemotherapy, radiation therapy, immunotherapy, and targeted therapy, are expanding the options available to patients. Continued research, clinical trials, and collaboration among healthcare professionals are crucial for further improving treatment outcomes and addressing the challenges associated with intraocular lymphoma.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL INTRAOCULAR LYMPHOMA TREATMENT MARKET – ANALYSIS & FORECAST, BY TYPE
    1. Vitreoretinal
    2. Uveal                                 
  6. GLOBAL INTRAOCULAR LYMPHOMA TREATMENT MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
    1. Methotrexate
    2. Cisplatin
    3. Rituximab               
  7. GLOBAL INTRAOCULAR LYMPHOMA TREATMENT MARKET – ANALYSIS & FORECAST, BY END USER
    1. Hospitals
    2. Specialty Clinics

INTRAOCULAR LYMPHOMA TREATMENT MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8936

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

Ergocalciferol Market by Application (Hypoparathyroidism, Rickets), Route of Administration (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Leptin Based Therapeutics Market by Application (Obesity, Diabetes), Type (Recombinant Leptin, Leptin Receptor Agonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

ABCA4 Retinopathy Therapeutics Market by Drug Type (Anti-VEGF Drugs, LBS-008), Age Group (Children, Adults), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) – Global Outlook & Forecast 2023-2031

Tocolytic Agents Market by Drug Class (Magnesium Sulfate, Betamimetics), Route of Administration (Oral, Parenteral) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.